Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
1. A therapeutic composition, comprising a pharmaceutically-acceptable carrier and an isolated glycyl-tRNA synthetase (GRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:1, (b) a fragment of (a) comprising at least 600 contiguous amino acids of SEQ ID NO:1, and (c) a variant of (a) having at least 95% identity to SEQ ID NO:1, where the GRS polypeptide has cell signaling activity and is at least about 90% pure, and where the composition is sterile and pyrogen-free.
2. The therapeutic composition of claim 1 , where the GRS polypeptide comprises at least 600 contiguous amino acids of SEQ ID NO:1 and has at least 95% identity to SEQ ID NO:1.
3. The therapeutic composition of claim 2 , where the GRS polypeptide has at least 98% identity to SEQ ID NO:1.
4. The therapeutic composition of claim 3 , where the GRS polypeptide comprises SEQ ID NO:1.
5. The therapeutic composition of claim 1 , where the GRS polypeptide is about 685 amino acids in length.
6. The therapeutic composition of claim 5 , where the GRS polypeptide consists essentially of SEQ ID NO:1.
7. The therapeutic composition of claim 1 , where the GRS polypeptide is at least about 95% pure.
8. The therapeutic composition of claim 1 , where the GRS polypeptide is at least about 99% pure.
9. The therapeutic composition of any of claims 1 - 5 , where the GRS polypeptide further comprises a heterologous fusion partner.
10. The therapeutic composition of claim 9 , where the heterologous fusion partner comprises an Fc region.
11. The therapeutic composition of claim 1 , where the GRS polypeptide is pegylated.
12. The therapeutic composition of claim 1 , where the GRS polypeptide is a recombinant polypeptide.
13. The therapeutic composition of claim 12 , where the recombinant polypeptide is produced in a bacterial cell.
14. The therapeutic composition of claim 12 , where the recombinant polypeptide is produced in a mammalian cell.
15. The therapeutic composition of claim 1 , where the GRS polypeptide is a synthetic polypeptide.
16. The therapeutic composition of claim 1 , where the GRS polypeptide induces production of IL-6, IL-8, MIP-1α, MIP-1β, GRO-α, or any combination thereof.
17. The therapeutic composition of claim 1 , where the composition is isotonic.
18. The therapeutic composition of claim 1 , where the composition is a sterile injectable solution.
19. The therapeutic composition of claim 1 , where the composition is formulated for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.
20. The therapeutic composition of claim 1 , where the composition comprises saline.
21. The therapeutic composition of claim 1 , where the saline comprises PBS.
22. The therapeutic composition of claim 1 , where the composition comprises a surfactant.